Abstract: The invention relates to novel pyrazolopyridine derivatives of the formula (I), wherein R1 represents hydrogen or a di-C1-6-alkylaminocarbonyl group, R2 represents a rest of the formula —O—CO—NR3R4, wherein R3 and R4 are the same or different and represent a rest of the group comprising optionally substituted C1-6 alkyl, optionally substituted C2-6 ?alkenyl, or optionally substituted C3-8 ? cycloalkyl: or which, together with the nitrogen atom to which they are bound, form a five- to seven-membered saturated heterocycle that may optionally contain an additional hetero atom from the group N, O, S and/or that may be optionally substituted, and to the salts, isomers and hydrates of said derivatives, as stimulants of the soluble guanylate cyclase and for use as agents for treating cardiovascular diseases, hypertonia, thromboembolic diseases and ischemia, sexual dysfunction or inflammations, and for treating diseases of the central nervous system.

Abstract: The invention relates to novel pyrazolopyridine derivatives of formula (I) wherein R1 represents H, Cl or NH2, and R2 and R3 form; together with the heteroatoms to which they are bonded, a five to six-membered heterocycle which can be saturated or partially unsaturated, can optionally contain at least one other heteroatom from the group N, O, S and can be optionally substituted. The invention also relates to salts, isomers and hydrates of said derivatives, in the form of stimulators of soluble guanylate cyclase and as agents for treating cardiovascular diseases, hypertonia, thrombo-embolic diseases and ischaemia, sexual dysfunction, inflammations, and diseases of the central nervous system.

Abstract: The invention relates to the use of stimulators of soluble guanylate cyclase, in particular, compounds of formula (I), wherein: R1 represents a saturated or unsaturated optionally substituted C3-8 cycloalkyl or represents a saturated, unsaturated or partially unsaturated heterocyclyl, which has 3 to 8 members, contains 1-4 heteroatoms from the set N, O, S, SO, SO2, and which can be optionally substituted; R2 represents H or NH2. The invention also relates to the use of the salts, isomers and hydrates of said compounds in order to produce medicaments used for treating osteoporosis.

Abstract: The present invention relates to new pyrazolopyridine derivatives of the formula (I) in which R1 represents 4-pyridinyl or 3-pyridinyl; R2 represents H, NH2 or halogen; and salts, isomers and hydrates thereof as stimulators of soluble guanylate cyclase and for use as agents for the treatment of cardiovascular disorders, hypertension, of thromboembolic disorders and ischaemia, sexual dysfunction or inflammation, and for the treatment of disorders of the central nervous system.

Abstract: The invention relates to the field of blood coagulation.

Abstract: The present invention relates to new pyrazolopyridine derivatives of the formula (I) 1

Abstract: The present invention relates to new heterocyclylmethyl-substituted pyrazole derivatives, processes for their preparation and their use as medicaments, in particular as medicaments for treatment of cardiovascular diseases.

Abstract: The present invention relates to new substituted pyrazole derivatives, processes for their preparation and their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.

Abstract: The present invention relates to new heterocyclylmethyl-substituted pyrazole derivatives, processes for their preparation and their use as medicaments, in particular as medicaments for treatment of cardiovascular diseases.

Abstract: The present invention relates to new heterocyclylmethyl-substituted pyrazole derivatives, processes for their preparation and their use as medicaments, in particular as medicaments for treatment of cardiovascular diseases.

Abstract: The present invention relates to new heterocyclylmethyl-substituted pyrazole derivatives, processes for their preparation and their use as medicaments, in particular as medicaments for treatment of cardiovascular diseases.

Abstract: The present invention relates to the new use of 1-benzyl-3-(substituted hetaryl)-fused pyrazole derivatives, some of which are known, of the general formula (I) in which R1 to R4 have the meaning indicated in the description, as medicaments, and to new active compounds, in particular to their use as vasodilators, if appropriate in combination with organic nitrates and NO donors and if appropriate in combination with compounds which inhibit the degradation of cGMP.

Abstract: The present invention relates to new heterocyclylmethyl-substituted pyrazole derivatives, processes for their preparation and their use as medicaments, in particular as medicaments for treatment of cardiovascular diseases.

Abstract: The invention relates to new 4-bicyclically substituted dihydropyridines of the general formula (I) ##STR1## in which R.sub.1 to R.sub.5 have the meaning given in the description, processes for their preparation and their use in medicaments, in particular in agents for the treatment of cardiovascular diseases.

Abstract: The invention relates to a process for the preparation of optically active ortho-substituted 4-aryl- or heteroaryl-1,4-dihydropyridines by oxidation and subsequent reduction from their opposite enantiomers.

Abstract: This invention relates to 3-quinolyl-substituted dihydropyridine derivatives, such as ##STR1## or a pharmaceutically acceptable salt thereof. These compounds are used in treating cardiovascular disease.

Abstract: Intermediate of the formula ##STR1## wherein R.sup.5 represents a cyclic, straight-chain or branched, saturated or unsaturated hydrocarbon radical having up to 12 carbon atoms, which is optionally interrupted up to twice in an identical or different manner by oxygen or sulphur, as intermediates for substituents on novel dihydropyridine cardiovascular compounds.

Abstract: The invention relates to new 4-bicyclically substituted dihydropyridines of the general formula (I) ##STR1## in which R.sub.1 to R.sub.5 have the meaning given in the description, processes for their preparation and their use in medicaments, in particular in agents for the treatment of cardiovascular diseases.

Abstract: The invention relates to new 2,6-disubstituted 4-quinolyl-dihydropyridines ##STR1## in which R.sub.1 to R.sub.5 have the meaning indicated in the description,processes for their preparation and their use in medicaments, in particular in compositions for the treatment of cardiovascular disorders.

Abstract: The invention relates to new 4-quinolyl-dihydropyridine esters of the general formula (I) ##STR1## in which R.sub.1 to R.sub.6 have the meaning given in the description, to processes for their preparation and to their use in medicaments, especially in agents for the treatment of cardiac circulatory disorders.